Assessment
Questionnaire

Have a symptom?
See what questions
a doctor would ask.
 
News » FDA approves new pulmonary arterial hypertension drug
 

FDA approves new pulmonary arterial hypertension drug

CoTherix Inc. has had it's new drug Ventavis approved by the FDA for use as an inhalant treatment for pulmonary arterial hypertension in patients with heart failure symptoms. Roughly 50,000 US people are believed to have the condition but only 15,000 have been diagnosed and are being treated.

Source: summary of medical news story as reported by Forbes

Related Disease Topics:

Article Source Details

About: FDA approves new pulmonary arterial hypertension drug

Date: 29 December 2004

Source: Forbes

URL: http://www.forbes.com/business/manufacturing/feeds/ap/2004/12/29/ap1732370.html

Related Medical Topics

This summary article refers to the following medical categories:

More News Topics

  • Pain medicine often prescribed for arthritis sufferers may prove beneficial for prostate cancer sufferers.
  • Pain more than just a sensation
  • Painkiller overdose kills man after horseback injury
  • Pancreas transplants improve diabetes and complications
  • Pancreatic cancer link to processed meats
  • Pancreatic cancer surgery less common in black men
  • Pancreatic cells implicated in PCOS
  • Paracetamol a safe and effective alternative to other anti-inflammatories
  • Paralysis and Guillain-Barre Syndrome
  • Parasites help heal stomach disorders
  • Parasites infect up to half of aboriginal population
  •  

    By using this site you agree to our Terms of Use. Information provided on this site is for informational purposes only; it is not intended as a substitute for advice from your own medical team. The information on this site is not to be used for diagnosing or treating any health concerns you may have - please contact your physician or health care professional for all your medical needs. Please see our Terms of Use.

    Home | Symptoms | Diseases | Diagnosis | Videos | Tools | Forum | About Us | Terms of Use | Privacy Policy | Site Map | Advertise